Peptide Boom: FDA Loosening Rules, Market Hits $52.6B, What You Need to Know
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
-
Narrado por:
-
De:
Market data highlights growth: the global longevity ingredients sector, overlapping biohacking, hit $984.27 million in 2025 and projects $1,706.40 million by 2033 at 7.12% CAGR, with peptides and amino acids claiming 15% share; North America leads at 35%.[2] March 2026 saw spermidine supplements named U.S. award finalists for autophagy support and NAD+ injectable pens launch at wellness centers, signaling consumer shifts toward cellular repair tools.[2] Peptides overall reached a $52.6 billion market, with GLP-1 adoption at 1 in 8 U.S. adults.[8]
New launches include U: The Mind Company's non-invasive brain device, an amplitude-modulated alternative to Neuralink, targeting focus and memory for biohackers; its Parkinson's trial is underway.[5] Weight-loss patches mimicking GLP-1 effects like Ozempic emerged as a 2026 trend, avoiding injections.[6]
No major deals, disruptions, or price shifts reported in the last week, but leaders like Finnrick Analytics address supply impurities via testing.[1] Compared to early 2026's NAD+ gut health studies, current buzz amplifies peptides amid policy thaw, boosting influencer-driven demand without evident consumer pullback. Industry responds by prioritizing ethical sourcing and trials for credibility.[1][2] (298 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Todavía no hay opiniones